$BHVN

Biohaven Ltd. (BHVN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. bhvn-20260803 0001935979 false 0001935979 2026-08-03 2026-08-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): A

Biohaven Pharmaceutical Holding Co. (BHVN) is set to report Q2 results, with analysts expecting a 75-cent per-share loss versus an 88-cent loss in the prior period. The pre-revenue biotech faces scrutiny over cash runway and timing for Phase 2/3 epilepsy trial RISE3 opakalim data in 2H 2026. Analysts cite restructuring to cut R&D spending and note a BofA Underperform downgrade and lower peak sales estimates.

Biohaven (BHVN) said a federal jury awarded it $1.0 million in a trade secret lawsuit against Avilar Therapeutics and RA Capital Management. The company frames the verdict as support for its intellectual property defense, while noting it does not change cash runway, trial timelines, or execution risk. The article also cites Simply Wall St community fair value estimates of about $23 to $61 per share.

Biohaven Pharmaceutical (BHVN) shares rose 2.1% to $14.62, supported by a Delaware federal jury verdict affirming Biohaven’s exclusive licensed rights to Yale’s MODA trade secret platform. The jury awarded $4 million in damages to Biohaven and Yale. Investors also cited upcoming clinical milestones for BHV-1300, BHV-1400, opakalim, and taldefgrobep alfa.

Biohaven Ltd. (BHVN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. bhvn-20260709 0001935979 false 0001935979 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): J

The article lists 12 “quality” stocks for long-term holding, using screens for forecasted >30% annual earnings growth and analyst favorability. It cites research on a quality premium and resilience in drawdowns. For Biohaven (BHVN), BofA cut its target to $11 and Deutsche Bank raised to $20; for Rogers (ROG), B. Riley raised to $200. No full list details provided.

Eurozone June economic confidence rose to 95.0 (+1.3), beating expectations of 94.3, and May M3 money supply increased 3.2% y/y vs 2.7% expected. Markets priced a ~7% chance of a 25 bp ECB hike on July 23. US stocks gained: KLAC +11%, PANW +9%, IRDM +25% on Rocket Lab’s ~$8B deal; several others rose or fell on upgrades, partnerships, and guidance.

Biohaven Ltd. (NYSE: BHVN) shares rose 12.66% to close at $13.62 on Wednesday, as investors looked ahead to upcoming pipeline updates. The company said it plans to start two clinical studies for endometrial and urothelial cancer candidates by month-end, with additional pivotal studies for BHV-1400 (IgAN) and BHV-1300 (Graves’ disease) later this year.

Biohaven Ltd. (NYSE:BHVN) rose about 9% mid-day Wednesday to around $10.97, after closing at $10.07. Shares traded as high as $10.95; volume was 864,521 shares, down 63% from average. Analysts cited include Citigroup’s $17 target and Canaccord’s $21; consensus target is $22.27. Biohaven reported Q1 EPS of -$0.88, slightly worse than -$0.86.

Biohaven (BHVN) is under scrutiny after its Q1 results and a new shelf registration. Despite a reduced net loss, its share price has fallen significantly, leading to questions about its valuation. The company's Price-to-Book ratio of 10.6x is below peers but well above the biotech sector, indicating that its current market value relies heavily on expectations for its extensive pipeline rather than current profitability.